Stocksigma LogoStocksigma Logo

NATCO Pharma Reports Q2FY27 Results with Consolidated PAT at ₹202.6 Crore

NATCO Pharma reported Q2FY27 consolidated revenue from operations of ₹967.3 crore, down 29.0% YoY from ₹1,363.0 crore, largely due to lower Lenalidomide

NATCO Pharma Reports Q2FY27 Results with Consolidated PAT at ₹202.6 Crore

Natco Pharma Ltd · Financial Result · 13 Nov 2026, 8:19 pm

NATCO Pharma Reports Q2FY27 Results with Consolidated PAT at ₹202.6 Crore NATCO Pharma reported Q2FY27 consolidated revenue from operations of ₹967.3 crore, down 29.0% YoY from ₹1,363.0 crore, largely due to lower Lenalidomide contributions despite base business growth. Consolidated net profit reached ₹202.6 crore versus ₹517.9 crore in Q2FY26. Segmentally, International Formulations generated ₹668.4 crore, Domestic Formulations rose to ₹145.7 crore, API contributed ₹61.3 crore, and Crop Health Sciences stood at ₹61.0 crore. The Board declared a second interim dividend of ₹1.25 per share (record date 19th Nov'26) and expanded its stake in Adcock Ingram to 49%.

Original exchange filing (PDF)

More announcements from Natco Pharma Ltd

All Natco Pharma Ltd announcements